Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
Journey Medical (Nasdaq: DERM) has scheduled the release of its year end 2024 financial results on Wednesday, March 26, 2025, after U.S. financial markets close. The commercial-stage pharmaceutical company, which specializes in marketing FDA-approved prescription pharmaceutical products for dermatological conditions, will host a conference call and audio webcast at 4:30 p.m. ET on the same day.
Interested U.S. participants can dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international) to join the conference call. Registration is available at https://dpregister.com/sreg/10197674/feaf5b7354. A live audio webcast will be accessible on the company's website and remain available for approximately 30 days after the call.
Journey Medical (Nasdaq: DERM) ha programmato il rilascio dei suoi risultati finanziari di fine anno 2024 per mercoledì 26 marzo 2025, dopo la chiusura dei mercati finanziari statunitensi. L'azienda farmaceutica in fase commerciale, specializzata nella commercializzazione di prodotti farmaceutici da prescrizione approvati dalla FDA per condizioni dermatologiche, ospiterà una conferenza telefonica e un webcast audio alle 16:30 ET dello stesso giorno.
I partecipanti statunitensi interessati possono chiamare il numero 1-866-777-2509 (nazionale) o 1-412-317-5413 (internazionale) per partecipare alla conferenza telefonica. La registrazione è disponibile su https://dpregister.com/sreg/10197674/feaf5b7354. Un webcast audio in diretta sarà accessibile sul sito web dell'azienda e rimarrà disponibile per circa 30 giorni dopo la chiamata.
Journey Medical (Nasdaq: DERM) ha programado la publicación de sus resultados financieros del año 2024 para el miércoles 26 de marzo de 2025, después del cierre de los mercados financieros de EE. UU. La compañía farmacéutica en etapa comercial, que se especializa en la comercialización de productos farmacéuticos de prescripción aprobados por la FDA para condiciones dermatológicas, llevará a cabo una conferencia telefónica y un webcast de audio a las 4:30 p.m. ET el mismo día.
Los participantes de EE. UU. interesados pueden marcar el 1-866-777-2509 (nacional) o el 1-412-317-5413 (internacional) para unirse a la conferencia telefónica. La inscripción está disponible en https://dpregister.com/sreg/10197674/feaf5b7354. Un webcast de audio en vivo estará accesible en el sitio web de la empresa y permanecerá disponible durante aproximadamente 30 días después de la llamada.
저니 메디컬 (Nasdaq: DERM)는 2025년 3월 26일 수요일, 미국 금융 시장이 마감된 후 2024년 연말 재무 결과 발표를 예정하고 있습니다. 피부과 질환을 위한 FDA 승인 처방약을 마케팅하는 상업 단계의 제약 회사인 저니 메디컬은 같은 날 오후 4시 30분 ET에 컨퍼런스 콜과 오디오 웹캐스트를 진행할 예정입니다.
관심 있는 미국 참가자는 1-866-777-2509 (국내) 또는 1-412-317-5413 (국제)로 전화하여 컨퍼런스 콜에 참여할 수 있습니다. 등록은 https://dpregister.com/sreg/10197674/feaf5b7354에서 가능합니다. 실시간 오디오 웹캐스트는 회사 웹사이트에서 이용 가능하며, 통화 후 약 30일 동안 제공됩니다.
Journey Medical (Nasdaq: DERM) a programmé la publication de ses résultats financiers de fin d'année 2024 pour le mercredi 26 mars 2025, après la fermeture des marchés financiers américains. L'entreprise pharmaceutique en phase commerciale, spécialisée dans la commercialisation de produits pharmaceutiques sur ordonnance approuvés par la FDA pour des conditions dermatologiques, organisera une conférence téléphonique et un webinaire audio à 16h30 ET le même jour.
Les participants américains intéressés peuvent composer le 1-866-777-2509 (national) ou le 1-412-317-5413 (international) pour rejoindre la conférence téléphonique. L'inscription est disponible sur https://dpregister.com/sreg/10197674/feaf5b7354. Un webinaire audio en direct sera accessible sur le site Web de l'entreprise et restera disponible pendant environ 30 jours après l'appel.
Journey Medical (Nasdaq: DERM) hat die Veröffentlichung ihrer Finanzergebnisse für das Jahr 2024 für Mittwoch, den 26. März 2025, nach dem Schließen der US-Finanzmärkte angesetzt. Das kommerziell tätige Pharmaunternehmen, das sich auf die Vermarktung von von der FDA zugelassenen verschreibungspflichtigen Arzneimitteln für dermatologische Erkrankungen spezialisiert hat, wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Audio-Webcast veranstalten.
Interessierte US-Teilnehmer können die Nummer 1-866-777-2509 (inland) oder 1-412-317-5413 (international) wählen, um an der Telefonkonferenz teilzunehmen. Die Registrierung ist unter https://dpregister.com/sreg/10197674/feaf5b7354 verfügbar. Ein Live-Audio-Webcast wird auf der Website des Unternehmens zugänglich sein und bleibt etwa 30 Tage nach der Konferenz verfügbar.
- None.
- None.
Company to host conference call to discuss financial results and provide a corporate update on March 26, 2025 at 4:30 p.m. ET
SCOTTSDALE, Ariz., March 19, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2024 financial results after the U.S. financial markets close on Wednesday, March 26, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 26, 2025 at 4:30 p.m. ET.
To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10197674/feaf5b7354. Please note that registered participants will receive their dial-in number upon registration.
A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
When will Journey Medical (DERM) release its 2024 year-end financial results?
How can investors join Journey Medical's (DERM) earnings conference call on March 26, 2025?
What time is Journey Medical's (DERM) earnings call scheduled for March 26, 2025?
Where can investors access the webcast of Journey Medical's (DERM) 2024 earnings call?
